Cite

HARVARD Citation

    Zhou, L. et al. (2022). Phase II study of apatinib combined with temozolomide in patients with advanced melanoma after failure of immunotherapy. Melanoma research. 32 (3), pp. 142-149. [Online]. 
  
Back to record